Document:

Exhibit 10.12

 

 

March 8, 2006

 

Gregory Went

 

Dear Greg,

 

We are quite excited to have you continue to be involved in NeuroMolecular Pharmaceuticals, Inc. (“NPI” or “the Company”). In this letter, I would like to summarize the proposed terms and conditions of your continued employment relationship with NPI.

 

I am pleased to offer you the full-time position of President and CEO working at our offices in Emeryville. Your position with the Company pursuant to the terms and conditions of this letter and accompanying Incentive Stock Option Agreement and Confidential Information and Invention Assignment Agreement. While employed by the Company, you will report to the BOD and have such duties and responsibilities consistent with your role. You agree to perform your duties faithfully and to the best of your abilities and to devote your full business efforts and time to the Company. Furthermore, while employed by the Company, you agree to not actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration without prior approval of the Company.

 

While employed by the Company, you will receive as compensation for your services an initial base salary of $250,000 on an annualized basis. Your salary will be paid periodically in accordance with normal Company payroll practices and be subject to the usual, required withholdings. In addition to this salary, in accordance with the terms of the accompanying Incentive Stock Option Agreement, at the next meeting of NPI’s Board of Directors you will be granted an option to purchase 375,000 shares of NPI Common Stock, par value $.001 per share, at an exercise price equal to the then-current fair market value. Such options will be granted in accordance with the terms of NPI’s 2002 Employee, Director and Consultant Stock Plan and shall vest as follows: (i) 20% on the first anniversary of the date of grant and (ii) 1/48 of the remaining shares per month thereafter. Your vesting shall accelerate in the event the Company is sold, merged or otherwise acquired (an “Acquisition”) according to the following schedule:

 

·                  20% if an Acquisition occurs within the first 12 months of the date of grant, and

 

1900 Powell St., Suite 210                                    Emeryville, CA 94608
 Office: 510.450.3508                                               Fax 510.428.0519

 

 

 

·                  if an Acquisition occurs during the period beginning on the first anniversary of the date of grant and ending on the fourth anniversary of the date of grant, all of the unvested shares shall vest, except for 1/2 of the then unvested shares which shall vest ratably for 12 months after the closing of the Acquisition;

 

In addition to this grant, assuming you are still employed by the Company, the BOD agrees that it will approve an additional option grant of 150,000 shares on or before the last day of the first fiscal year in which commercial sales of NPI products exceed $5 Million USD. Such option grant shall have an exercise price per share equal to the fair market value per share of the Company’s common stock as of the date of grant and shall vest in full on the last day of the Company’s fiscal quarter in which the Company has received an aggregate of $50 Million USD in gross revenue for that fiscal year. If the Company has not received $50 Million USD in gross revenue for any fiscal year prior to January 1, 2011, the option shall terminate. These shares shall not be subject to the acceleration provision outlined in the above mentioned Option Agreement.

 

During your employment with the Company, you will be eligible to participate in the employee benefit plans currently and hereafter maintained by the Company of general applicability to other employees of the Company. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document. As part of these benefits, you will be entitled to four (4) weeks paid vacation per year, which will accrue at the rate of 1.25 days per month. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time, and the provision of benefits to you in no way changes or impacts your status as an “at-will” employee.

 

The Company considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. Consequently, as a condition of this offer of employment, you are required to sign the Confidential Information and Invention Assignment Agreement enclosed with this letter.

 

You should understand that your employment with the Company is “at-will,” and may be terminated by you or the Company at any time and for any reason. No provision of this offer letter or the accompanying Incentive Stock Option Agreement and Confidential Information and Invention Assignment Agreement shall be construed to create an express or implied employment contract, or a promise of employment for any specific period of time. This offer letter and the accompanying Incentive Stock Option Agreement and Confidential Information and Invention Assignment Agreement represent the entire agreement and understanding between you and the Company concerning your employment relationship with the Company, and supersede in their entirety any and all prior agreements and understandings concerning your employment relationship with the Company, whether written or oral.

 

1900 Powell St., Suite 210                                     Emeryville, CA 94608
 Office: 510.450.3508                                                Fax 510.428.0519

 

 

 

The terms and conditions set forth in this offer letter will inure to the benefit of any successor of the Company. In the event any of the terms and conditions set forth in this offer letter become, or are determined to be, illegal, unenforceable or void, all other terms and conditions will continue in full force and effect.

 

This letter will be governed by the laws of the state of California, with the exception of its conflict of laws provisions.

 

Please call me at (510) 903-3402 if you have any questions. I am excited to welcome you to the Company, and I look forward to your participation in the Company’s future success. Please sign below to indicate your acceptance and agreement to the terms set forth in this offer letter and return the signed offer letter to me.

 

	
Best regards,
    	
 
    
	
 
    	
 
    
	
/s/ William W. Ericson
    	
 
    

 

William Ericson

BOD Member

Neuromolecular Pharmaceuticals

 

Agreed and Accepted:

 

I, Gregory T. Went, have read, understand, and accept employment on the terms and conditions outlined in this letter. I am not relying on any representations made to me by anyone other than as set forth above.

 

	
/s/ Gregory T. Went
    	
 
    
	
Print Name
    	
 
    
	
 
    	
 
    
	
3.27.06
    	
 
    
	
Date
    	
 
    

 

1900 Powell St., Suite 210                                     Emeryville, CA 94608
 Office: 510.450.3508                                                Fax 510.428.0519Exhibit 10.13

 

June 8, 2011

 

Mr. Tony Rimac

 

Dear Tony,

 

We are quite excited to have you involved in Adamas Pharmaceuticals, Inc, (“the Company”).  In this letter, I would like to summarize the proposed terms and conditions of your employment relationship with the Company.

 

Title and Responsibilities.  I am pleased to offer you the full-time position of Chief Financial Officer working at our offices in Emeryville, CA.  Your position with the Company, pursuant to the terms and conditions of this letter and accompanying Confidential Information and Invention Assignment Agreement, will commence on July 25, 2011.  While employed by the Company, you will report to the CEO and your duties and responsibilities consistent with your title will include the following functions: accounting, financial planning and analysis, contract management, human resources, information technology, with additional responsibilities consistent with your role added over time.

 

Salary and Bonus.  While employed by the Company, you will receive as compensation for your services an initial annual base salary of $275,000, with $25,000 deferred until the close of the next qualified financing after the Sereis AA in excess of $2,000,000.  Your salary will be paid periodically in accordance with normal Company payroll practices and be subject to the usual, required withholdings.  You will be subject to additional stock and cash bonuses based upon the achievement of certain milestones.

 

Stock Options.  In addition, subject to the approval of the Company’s Board of Directors or its Compensation Committee, it will be recommended that you be granted an option to purchase 100,000 shares of Company Common Stock.  The exercise price per share will be determined by the Board of Directors or Compensation Committee when the option is granted.  Such option will be subject to the terms and conditions applicable to options granted under the Company’s 2007 Stock Plan (the “Plan”) as described in the Plan and the applicable Stock Option Agreement.  Provided you remain in continuous service to the Company on each date, you will vest in 20% of the option shares on the 12 month anniversary of your employment commencement date and the balance will vest in equal monthly installments on the first clay of each of the next 48 months, as described in the applicable Stock Option Agreement.

 

 

1

 

Benefit Plans.  During your employment with the Company, you will be eligible to participate in the employee benefit plans currently and hereafter maintained by the Company of general applicability to other employees of the Company.  Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit from the plan is governed solely by the applicable plan document.

 

Paid Time Off.  As part of these benefits, you will be entitled to paid time off (“PTO”) in accordance with the Company’s PTO policy as in effect from time to time.  Currently, the Company offers full-time employees 21 days of PTO per calendar year.  The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time in accordance with applicable law, and the provision of benefits to you in no way changes or impacts your status as an “at-will” employee.

 

Confidential Information.  The Company considers the protection of its confidential information, proprietary materials and goodwill to be extremely important.  Consequently, as a condition of this offer of employment, you are required to sign the Confidential Information and Invention Assignment Agreement enclosed with this letter.

 

Conflicting Outside Employment.  While employed by the Company, you may not work as an employee or consultant of any other organization or engage in any other activities which conflict or interfere with your employment obligations to the Company, including working for a competitive organization, or undertaking any activities that could create a conflict of interest, without prior approval.  Approved outside activities are attached on Exhibit A.

 

At-Will Employment.  You should understand that your employment with the Company is “at-will,” and may be terminated by you or the Company at any time and for any reason.  No provision of this offer letter or the accompanying Confidential Information and Invention Assignment Agreement shall be construed to create an express or implied employment contract, or a promise of employment for any specific period of time.  This offer letter and the accompanying Confidential Information and Invention Assignment Agreement supersede in their entirety any and all prior agreements and understandings concerning your employment relationship with the Company, whether written or oral.

 

Introductory Period.  The first ninety days of your employment with the Company will be an introductory period and at the end of that period the Company will conduct a review of your performance.  Completion of this introductory period does not change in any way your status as an “at-will” employee and therefore, you and the Company have the right to end your employment for any reason at any time during or after the introductory period.

 

Authorization to Work.  This offer is conditioned upon the following:  (1) you presenting evidence of your authorization to work in the United States and your identity sufficient to allow the Company to complete the Form 1-9 required by law; (2) satisfactory completion of a background and reference check; (3) passing the required pre-employment drug test; and (4) your signature on the Confidential Information and Invention Agreement.

 

Modification and Governing Law.  This agreement may not be modified except in a writing signed by an officer of the Company and you.  The unenforceability of any provision of 

 

2

 

this agreement will not affect the validity or enforceability of any other provision of the agreement.  This letter will be governed by the laws of the state of California.

 

Please call me at (510) 450-3502 if you have any questions.  I am excited to welcome you to the Company, and I look forward to your participation in the Company’s future success.  Please sign below to indicate your acceptance and agreement to the terms set forth in this offer letter and return the signed offer letter to me.

 

	
Best regards,
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Gregory T. Went, Ph.D.
    	
 
    

 

Gregory T. Went, Ph.D.

CEO and Chairman

Adamas Pharmaceuticals, Inc.

 

ACCEPTANCE OF EMPLOYMENT OFFER

 

I, ANTHONY RIMAC, have read, understand, and accept employment on the terms and conditions outlined in this letter.  I am not relying on any representations made to me by anyone other than as set forth above.

 

	
/s/ Tony Rimac
    	
 
    
	
Tony Rimac
    	
 
    
	
 
    	
 
    
	
10/JUNE/11
    	
 
    
	
Date
    	
 
    

 

3

 

Appendix A

 

The following will be considered approved “Outside Activities”

 

·                  Participation as a Board and/or Committee Member of a Private and/or Public Company that is not competitive with Adamas.

 

·                  Participation as a Board and/or Committee Member of a Non-profit Organization

 

·                  Consulting Advice to CEO and Board/Investors of Aerovance, Inc. through anticipated corporate transaction, however, in no case to exceed beyond 12/31/11

 

·                  Consulting Advice to CEO and Board/Investors of SentreHEART, Inc. through anticipated corporate transaction and/or financing as the case may be, however, in no case to exceed beyond 12/31/11

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]